Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55513-0730-01 55513-0730 Denosumab XGEVA 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Nov 18, 2010 In Use
00069-4494-02 00069-4494 Elranatamab-bcmm Elrexfio 76.0 mg/1.9mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug 15, 2023 In Use
70121-1754-01 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 15, 2022 Oct 31, 2028 In Use
55513-0956-01 55513-0956 Panitumumab Vectibix 400.0 mg/20mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 10, 2006 In Use
55513-0730-21 55513-0730 Denosumab XGEVA 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Apr 15, 2025 In Use
00002-8926-01 00002-8926 Olaratumab Lartruvo 10.0 mg/mL Immunotherapy Monoclonal Antibody PDGFR Intravenous Oct 19, 2016 Nov 27, 2020 No Longer Used
55513-0141-21 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jul 1, 2025 In Use
66302-0014-01 66302-0014 Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 Intravenous Mar 10, 2015 In Use
83077-0100-02 83077-0100 Zenocutuzumab BIZENGRI 20.0 mg/mL Immunotherapy Monoclonal Antibody HER2, HER3 Intravenous Dec 4, 2024 In Use
83257-0029-41 83257-0029 Denosumab-kyqq BOSAYA 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jan 5, 2026 In Use
55513-0132-21 55513-0132 trastuzumab-anns Kanjinti 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jul 1, 2025 In Use
00173-0808-02 00173-0808 Ofatumumab Arzerra Immunotherapy Monoclonal Antibody CD20 Oct 26, 2009 Mar 31, 2012 No Longer Used
67457-0991-15 67457-0991 Trastuzumab OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov 29, 2019 Feb 28, 2027 In Use
00006-5034-02 00006-5034 Ontruzant Ontruzant Immunotherapy Monoclonal Antibody HER2 Intravenous Apr 15, 2020 Sep 30, 2023 No Longer Used
57894-0450-01 57894-0450 Teclistamab-cqyv TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
72606-0059-01 72606-0059 Denosumab-bmwo Denosumab-BMWO 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Sep 10, 2025 In Use
50242-0070-86 50242-0070 Obinutuzumab Gazyva 1000.0 mg/40mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov 4, 2013 In Use
00006-5033-02 00006-5033 Trastuzumab Ontruzant 150.0 mg/1 Immunotherapy Monoclonal Antibody HER2 Intravenous Apr 15, 2020 Sep 30, 2023 No Longer Used
50242-0125-01 50242-0125 Glofitamab Columvi 2.5 mg/2.5mL Immunotherapy Monoclonal Antibody CD20, CD3 Intravenous Jun 15, 2023 In Use
42747-0761-01 42747-0761 mogamulizumab-kpkc POTELIGEO 4.0 mg/mL Immunotherapy Monoclonal Antibody CCR4 Intravenous Aug 8, 2018 In Use
70121-1755-01 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 15, 2022 Oct 31, 2028 In Use
00078-0669-13 00078-0669 Ofatumumab Arzerra 20.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Feb 1, 2016 Jan 31, 2026 In Use
83616-0106-11 83616-0106 Vusolimogene oderparepvec-wtpg Tudriqev 1000000.0 [PFU]/mL Immunotherapy Oncolytic Viral Therapy GALV-GP-R, GM-CSF INTRATUMOR Sep 4, 2026 In Use
83616-0107-11 83616-0107 Vusolimogene oderparepvec-wtpg Tudriqev 10000000.0 [PFU]/mL Immunotherapy Oncolytic Viral Therapy GALV-GP-R, GM-CSF INTRATUMOR Sep 4, 2026 In Use
64067-0216-01 64067-0216 Methoxsalen UVADEX 20.0 ug/mL Chemotherapy Photosensitizing Agent Psoralen Extracorporeal Feb 25, 1999 In Use

Found 12611 results — Export these results